By Elena Voss, MPH, Public Health Researcher. Medically reviewed by Dr. Lila Carter, MD, MPH, Board-Certified Obesity Medicine.
Andrea, a 44-year-old marketing director in Charlotte, NC, stood up from her desk on a Tuesday afternoon in her sixth week on semaglutide and promptly sat back down. "The room sort of tilted sideways," she told her prescriber at a follow-up visit. "My BP reading at the pharmacy was 88/54. I've never seen numbers that low in my life." Her prescriber paused her dose escalation, bumped up her daily water target to 80 ounces, and added a half-teaspoon of salt to her morning routine. Within ten days, her readings climbed back above 100 systolic. She resumed the same dose without incident.
Andrea's experience sits squarely in the middle of roughly 1,900 monthly U.S. searches around "dangerously low blood pressure like to ozempic." The question gets asked often enough that a clear, specific answer is overdue. So here it is.
This article is part of the FormBlends ultimate guide to compounded tirzepatide and the Drug Comparison (Sema vs Tirz vs Brand) hub.
Key takeaways
- Most GLP-1 side effects are gastrointestinal, dose-dependent, and most prominent in the first 4 to 12 weeks at a new dose.
- Non-pharmacologic mitigation (hydration, smaller meals, lower-fat meals, fiber, meal timing) is the first line.
- Severe abdominal pain, persistent vomiting, or signs of an allergic reaction are not routine side effects and warrant urgent care.
- Compounded tirzepatide is not FDA-approved. The FDA does not pre-review compounded medications.
Why Blood Pressure Drops on GLP-1s (and When It's Actually Dangerous)
The dizziness-and-lightheadedness version of "low blood pressure on Ozempic" is, in most cases, a dehydration story. GLP-1 receptor agonists slow gastric emptying, blunt thirst cues, and reduce overall food and fluid intake. People eat less, drink less, and sometimes forget they're doing both. Blood pressure drifts down. Orthostatic symptoms follow.
Here's the thing: for many people on these medications, a modest blood pressure reduction is actually a benefit. The STEP trials and SURMOUNT trials consistently showed mean reductions in systolic BP. The concern flips when systolic drops below 90, or when someone gets dizzy standing, or when they're already on antihypertensives that were calibrated for a heavier body eating more sodium.
Signs that cross the line from "manageable side effect" into "get evaluated now" include persistent lightheadedness that doesn't resolve with sitting, fainting or near-fainting, heart rate changes, severe persistent abdominal pain (especially radiating to the back, which can signal pancreatitis), severe vomiting, signs of dehydration, gallbladder symptoms (right upper quadrant pain, fever, jaundice), and any allergic reaction.
The boring truth is that most low-BP episodes on GLP-1 therapy resolve with deliberate hydration and, occasionally, a conversation with a prescriber about adjusting existing blood pressure medications.
How GLP-1 and GIP Receptors Actually Work Here
GLP-1 receptor agonists bind to and activate the GLP-1 receptor, which is expressed on pancreatic islet cells, on central nervous system structures that regulate appetite, and on cells throughout the gastrointestinal tract. The downstream effects: glucose-dependent insulin secretion, suppression of inappropriate glucagon release, slowing of gastric emptying, and a centrally mediated reduction in food reward and hunger.
Get medications from a trusted source
FormBlends sources through 503A compounding pharmacies with third-party purity testing on every batch.
Start Free Assessment →Tirzepatide adds a second mechanism. It's a dual GIP and GLP-1 receptor agonist. The added GIP receptor activity is the headline mechanistic difference from pure GLP-1 agonists like semaglutide and liraglutide. Pre-clinical and translational work suggests GIP agonism may improve the GI tolerability ceiling at higher doses and affect adipose-tissue physiology, but the clinical contribution of GIP activity remains an active research area.
Think of it like a stereo system with two channels instead of one. Both channels play music; the question researchers are still working on is exactly how much each channel contributes to the final sound.
Semaglutide and liraglutide differ from each other primarily in pharmacokinetics. Semaglutide has a much longer half-life (enabling once-weekly dosing). Liraglutide requires daily injection.
The figures and protocols cited throughout this guide trace back to peer-reviewed publications and FDA prescribing information for the relevant brand-name products. Compounded formulations are not FDA-reviewed, and any practical guidance about compounded products reflects the standard clinical protocol for the underlying active ingredient.
Getting the Dosing Math Right (Because Getting It Wrong Is How Problems Start)
Dosing math for compounded GLP-1 products comes down to two numbers: the concentration of the vial and the prescribed dose in milligrams. The volume to draw equals the prescribed dose divided by the concentration. The number of units on a U-100 syringe equals the volume in mL multiplied by 100.
Worked example. Vial concentration: 10 mg/mL. Prescribed dose: 2.5 mg. Volume to draw: 2.5 ÷ 10 = 0.25 mL. On a U-100 syringe, 0.25 mL = 25 units. Draw to the 25-unit mark.
Same dose, different concentration. Vial concentration: 5 mg/mL. Prescribed dose: still 2.5 mg. Volume to draw: 2.5 ÷ 5 = 0.5 mL. On a U-100 syringe, 0.5 mL = 50 units. Draw to the 50-unit mark.
The arithmetic is simple in isolation. Where this falls apart in practice is when the pharmacy ships a different lot or a different fill volume and the patient doesn't re-read the label. The unit number that worked last month may correspond to a completely different milligram dose if the concentration changed. Always re-read the label at every fill. Every single time.
What the Trials Actually Show
SURMOUNT-1 (Jastreboff et al., NEJM 2022) evaluated tirzepatide in adults with obesity without type 2 diabetes over 72 weeks. SURMOUNT-3 (Wadden et al., Nat Med 2023) evaluated tirzepatide following a 12-week intensive lifestyle intervention lead-in. SURMOUNT-4 (Aronne et al., JAMA 2024) evaluated the effect of continued versus withdrawn tirzepatide on weight maintenance.
Trial averages are exactly that: averages. The trials report a wide distribution around the mean. These figures describe what a representative trial participant experienced under trial conditions, not what any individual outside the trial will necessarily experience. Someone at the 25th percentile and someone at the 75th percentile had very different trajectories on the same protocol.
Related reading in this cluster
- Ozempic And Diverticulitis: Complete Guide
- Zepbound Insomnia: Complete Guide
- What color is semaglutide with b12?
How Clinicians Adjust When Side Effects Show Up
The clinical knobs available at a routine follow-up include: hold at current dose, advance to the next step, drop back to the previous step, extend the interval between doses by one or two days, or temporarily pause and resume at a lower step. Each option has a place in the standard protocol toolkit.
Mild dehydration, specifically, can present as dizziness, lightheadedness, or feeling cold. Because GLP-1 medications can blunt thirst cues and reduce overall intake, deliberate hydration is not optional advice. It's part of the side-effect mitigation plan.
Adjustments to the standard escalation are not unusual. Roughly half of patients in real-world cohorts experience side effects significant enough to merit a temporary pause or slower escalation at some point in the first six months. This is anticipated and managed within the standard protocol. It is not a sign that the medication "isn't working for you."
Injection-site reactions (small red bumps, itching, transient bruising) are common and usually self-limited. Rotating the injection site is the first line of mitigation.
My honest take: the biggest risk factor for avoidable side effects isn't the medication itself. It's patients who escalate faster than prescribed because they read a Reddit thread about someone's results at the maximum dose.
Special Populations and Genuine Contraindications
Special-population considerations include severe renal or hepatic impairment, history of pancreatitis, personal or family history of medullary thyroid carcinoma or MEN2 syndrome (a contraindication for GLP-1 receptor agonists), severe gastroparesis, and active gallbladder disease. Each of these affects the risk-benefit calculation and may change the protocol entirely.
Pregnancy and breastfeeding are not appropriate windows for GLP-1 therapy. Patients planning pregnancy are typically advised to discontinue at least two months before attempting to conceive, depending on the specific medication.
Patients on insulin or insulin secretagogues require dose adjustments to those medications when GLP-1 therapy is added, to reduce hypoglycemia risk. This is a prescriber-led decision and should not be improvised.
Related reading from adjacent topics
- Does humana cover ozempic?
- Evaluating Compounded GLP-1 Telehealth Programs: A Buyer Framework (Industry-Specific)
Three Myths That Keep Circulating
"More is better." Above the trial-validated dose range, additional drug does not produce a proportional increase in efficacy and may worsen tolerability. The escalation schedule reflects published trial design, not arbitrary caution.
"Side effects mean it's working." Side effects correlate with dose escalation and individual sensitivity, not with the magnitude of weight loss. People with minimal GI symptoms can still lose meaningful weight. People with significant GI symptoms do not necessarily lose more.
"The medication stops working after a few months." Plateaus are a normal part of weight-loss trajectories and do not equal loss of pharmacologic effect. SURMOUNT-1 and STEP 1 show continued gradual losses through their 68-to-72-week windows, with most of the absolute change occurring in the first half of the trial.
What We Still Don't Know
What is the optimal duration of therapy? SURMOUNT-4 and the STEP-4 extension both demonstrated regain after discontinuation, supporting the view of these medications as chronic therapy, but the long-horizon comparative-effectiveness data are still maturing.
How does the GIP arm of tirzepatide contribute to the observed clinical effect, and can selective GIP modulation enhance outcomes further? Active research area, no settled answer yet.
How do these medications interact with longer-term cardiometabolic outcomes beyond weight and A1c? SELECT showed cardiovascular benefit for semaglutide in a defined high-risk population. Comparable long-horizon outcome data for tirzepatide are still accumulating.
Frequently asked questions
Is this question something I should discuss with a clinician?
Yes. Any question that affects how a prescription medication is dosed, stored, or administered is worth raising with your prescriber. The answer in this article is general education, not a substitute for individualized clinical guidance.
How long do these side effects usually last?
Most GLP-1 gastrointestinal side effects are most prominent in the first 4 to 12 weeks at a new dose and tend to improve as the body adjusts. Persistent or worsening symptoms warrant a call to the prescriber.
Can I take over-the-counter medications to manage the symptoms?
Some non-prescription options (such as fiber supplements for constipation or acid reducers for reflux) are commonly used. Confirm with your prescriber or pharmacist before adding anything, especially if you take other prescription medications.
Should I skip a dose to let the side effects pass?
Do not skip or alter doses without speaking to your prescriber. A coordinated dose hold or step-down is a routine option; an improvised skip is not.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not an FDA-approved drug. The FDA does not review compounded medications for safety, effectiveness, or quality prior to dispensing. Compounded medications are dispensed under personalized prescriptions through state-licensed pharmacies when a prescriber determines a personalized formulation is clinically appropriate.
Should my other blood pressure medications be adjusted when I start a GLP-1?
Potentially. If you are already on antihypertensives, your prescriber should be monitoring your readings more frequently during the first few months of GLP-1 therapy. Do not adjust blood pressure medications on your own.
How much water should I actually be drinking?
A common clinical target is 64 to 80 ounces per day, but individual needs vary based on body size, activity level, and climate. Your prescriber can give you a personalized number. The point is: don't wait until you're thirsty.
Continue the series
Important Safety Information
This article is for educational purposes only and is not medical advice. Compounded tirzepatide and compounded semaglutide are not FDA-approved drugs. The FDA does not review compounded medications for safety, effectiveness, or quality before they are sold. Compounded medications should only be used when a licensed prescriber determines a personalized formulation is clinically appropriate. Do not start, stop, or modify any prescription medication without speaking with a licensed healthcare provider. If you experience symptoms of a serious reaction, including severe abdominal pain, signs of pancreatitis, vision changes, persistent vomiting, signs of an allergic reaction, or thoughts of self-harm, seek emergency care immediately.
FormBlends sells only compounded semaglutide and compounded tirzepatide through licensed U.S. pharmacies after a telehealth evaluation by an independent prescriber. Eligibility, pricing, and formulation are determined on a case-by-case basis.
About this article
Written by Elena Voss, MPH (Public Health Researcher). Medically reviewed by Dr. Lila Carter, MD, MPH (Board-Certified Obesity Medicine). FormBlends content is reviewed by licensed U.S. clinicians prior to publication. The clinical decisions described above are general education only and should not replace individualized advice from your own healthcare provider.